Pharmaceuticals & Biotechnology

AYTU BIOPHARMA, INC CEO pay

Joshua R. Disbrow, Chief Executive Officer since April 2015. Fiscal year 2026, as reported to the SEC.

Total compensation

$845K

$844,854 for fiscal 2026: the Summary Compensation Table total, with stock and option awards at their grant-date value.

Definitive proxy statement, filed 2026-10-22SEC accession number 0001437749-26-033276

In context

The median chief executive among 289 Pharmaceuticals & Biotechnology companies with under $100M in revenue was paid $2.3M. The middle half ranged from $933K to $4.3M.

Joshua R. Disbrow's total is below that median.

See how your pay compares to AYTU BIOPHARMA, INC's peers

CEOSalary breaks this total into salary, bonus, stock and option awards, builds a peer set of comparable companies around it, and places your own package against them, with every figure cited to its filing.

Start a 3-day trial

Source: AYTU BIOPHARMA, INC's definitive proxy statement (SEC Form DEF 14A), Summary Compensation Table, fiscal year 2026. Figures are as reported by the company and are not adjusted or estimated. Context figures are from CEOSalary's snapshot of SEC filings as of 2026-11-01. Not financial, legal or compensation-consulting advice.